Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleolar protein 4 (NOL4) is a nucleolar-localized protein encoded by the NOL4 gene in humans. It is predicted to enable RNA binding activity and is involved in various cellular processes, primarily within the nucleolus[1][2][5]. NOL4 has been identified as a methylation target in several cancers, including cervical and head and neck cancer, indicating a possible role in tumorigenesis[3]. Though implicated in cancer, it is not established as a classical therapeutic target (such as a receptor, enzyme, or transporter). NOL4 is associated with certain neuroendocrine tumors, but detailed mechanisms and therapeutic targeting remain to be defined[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleolar protein 4 (NOL4).